Introduction
Invariant natural killer T (iNKT) cells are unconventional regulatory and effector T cells that recognize glycolipid antigens presented by the major histocompatibility complex (MHC) class I-like molecule CD1d [1, 2] . They can be activated by a number of endogenous and bacterial glycosphingolipids [3, 4] , but the xenogeneic glycolipid, α-galactosylceramide (α-GalCer), a potent agonist for murine and human iNKT cells [5] has been used as the prototype antigen for most studies on iNKT cells. Upon in vitro activation with α-GalCer, iNKT cells kill a range of tumor cell lines [6] , rapidly release cytokines [2, 7, 8] , promote maturation of dendritic cells (DC) into antigen-presenting cells (APC) [9] [10] [11] [12] and promote maturation of B cells into antibody-secreting plasma cells [13, 14] . Studies in murine models of disease have demonstrated critical roles for iNKT cells in the prevention and reversal of tumor growth, prevention of autoimmune disease, and immunity against a diversity of microbial pathogens [15] [16] [17] [18] . Numerical and functional deficiencies of iNKT cells have been reported in humans with various diseases [19, 20] but clinical trials involving α-GalCer stimulation of iNKT cells have yielded disappointing results [21, 22] .
A notable feature of iNKT cells is their ability to rapidly release cytokines that exert major effects on early and delayed adaptive immunity against tumors and infectious pathogens [2, 7, 8] . α-GalCer stimulation of murine and human iNKT cells results in the simultaneous production of the Th1 cytokine interferon-γ (IFN-γ) and the Th2 cytokines IL-4 and IL-13 [7, 8] . Th1 cytokines are thought to be critical for the antitumor effects of α-GalCer, whilst the Th2 cytokines can attenuate antitumour immunity and autoimmune disease pathology [17, 23, 24] . Therefore, the efficacy of α-GalCer may be limited by reciprocal inhibition exhibited by Th1 and Th2 cytokines and this may be reflected in the low efficacy of α-GalCer for the treatment of solid tumors in a phase I study [25] . Hence, a number of α-GalCer derivatives and analogues have been synthesised to develop compounds which can selectively induce particular responses in iNKT cells. Modifications to the galactose residue revealed that the α-anomeric configuration is a key pharmacophoric element of α-GalCer [26, 27] . Modifications to the acyl chains, including shortening [28] [29] [30] and the introduction of double bonds [31] resulted in iNKT cell ligands that preferentially stimulated Th2 cytokine secretion, whilst the addition of aromatic groups
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Substitution of the O-glycosidic linkage in α-
GalCer with a C-glycosidic linkage resulted in a Th1-inducing compound with 100-fold greater antimetastatic activity in mice [34] . Silk and co-workers [35] identified threitolceramide as a weak iNKT cell agonist, which led to the advantage for some applications of less consequent killing of CD1d + APC by iNKT cells and lowered anergic effects on repeated exposure.
We recently synthesised a thioglycoside analogue of α-GalCer (α-S-GalCer; Figure   1 ) using a novel approach that resulted in the galactosyl thiol being produced exclusively as α-anomers [36] . Here we show that this α-S-GalCer compound binds CD1d and stimulates cytotoxicity and cytokine secretion by human peripheral blood iNKT cell lines and renders them capable of inducing maturation of DCs into APCs. This is the first demonstration of a thioglycoside analogue of α-GalCer that activates iNKT cells. Its increased stability in biological systems and enhanced flexibility around the anomeric linkage places α-S-GalCer and its substituted derivatives as a potentially superior family of ligands, compared to α-GalCer, for therapeutic activation of human iNKT cells.
Materials and Methods

Antibodies and flow cytometry
Fluorochrome-conjugated monoclonal antibodies (mAb) specific for human CCR7, CD1d, CD3, CD4, CD8, CD11c, CD14, CD40, CD54, CD80, CD83, CD86, CD107a, HLA-DR, the Vα24 and Vβ11 chains that form the T cell receptor (TCR) present on iNKT cells, the complementarity-determining region-3 of the invariant Vα24Jα18 TCR chain (6B11) and isotype control mAbs were obtained from BD Biosciences (Oxford, UK), Immunotools (Friesoythe, Germany), R&D Systems (Abingdon, UK), eBioscience (Hatfield, UK) or
Coulter Immunotech (Galway, Ireland). Following staining, cells were analysed using a FACSCalibur flow cytometer with CellQuest software (BD Biosciences).
Generation of iNKT cell lines
Peripheral blood mononuclear cells (PBMC) were prepared from healthy blood donors by standard density gradient centrifugation over Lymphoprep (Nycomed Pharma, Oslo, Norway). iNKT cells were sorted from PBMC by staining with a phycoerythrin (PE)-conjugated anti-iNKT cell mAb (clone 6B11) followed by positive selection of the PEpositive cells by magnetic bead separation using anti-PE magnetic beads (Miltenyi Biotec, Bergisch-Gladbach, Germany). In some cases iNKT cells were enriched by flow cytometric sorting of 6B11-positive cells using a MoFlo™ XDP Cell Sorter (Beckman Coulter).
Sorted iNKT cells were expanded in vitro using two different methods that were developed in our laboratory and yielded sufficient numbers of iNKT cells for functional studies. Method 1 involved culturing 1,000 iNKT cells in complete RPMI medium (RPMI 1640 containing 0.05 mM L-glutamine, 0.05 mM β-mercaptoethanol, 10% HyClone fetal calf serum or FCS, 1% penicillin-streptomycin, 1% fungizone and 25mM HEPES; Gibco-BRL, Paisley, UK and Thermo-Scientific, Logan, UT) and stimulating them with 1 µg/ml phytohaemagglutinin (PHA-P; Sigma-Aldrich, Dublin, Ireland) and 250 U/ml IL-2 (R&D Systems, Abingdon, UK) in the presence of an excess (2x10 5 ) of irradiated allogeneic M A N U S C R I P T hours, the medium was supplemented with 100 U/ml of IL-2 and cells were cultured for 2 weeks, after which spent medium was replaced with complete RPMI containing 50 U/ml IL-2. Cells were split into multiple wells when confluency exceeded 50%. Purity and phenotype of iNKT cell lines were assessed by flow cytometry after staining the cells with mAbs specific for CD3, 6B11, Vα24, Vβ11, CD4 and CD8.
Glycolipids
α-GalCer (KRN7000) was purchased from Funakoshi Co. Ltd, (Tokyo, Japan). The thioglycoside analogue of α-GalCer (α-S-GalCer) was synthesized as described previously [36] . Briefly, α-galactosyl thiol was prepared from the benzylated 1,6-anhydrogalactose in very high yield, and then coupled with the electrophilic sphingoid iodide under phase transfer conditions, to give the α-linked product. Notably, the α-galactosyl thiol was produced exclusively as α-anomer, which made the purification simple and straightforward.
Eventually the α-S-GalCer was synthesized in a linear sequence of 14 steps with 3% overall yield.
Glycolipid stocks were prepared by suspending solid α-GalCer or α-S-GalCer in dimethylsulphoxide (DMSO) to a final concentrations of 1 mM by heating for 2 min at 
Analysis of cytokine secretion by iNKT cells
iNKT cells were stimulated in vitro using mock-transfected or CD1d-transfected HeLa [33] or C1R cells [7] were assayed for granulocyte-monocyte colony-stimulating factor (GM-CSF), IFN-γ, IL-4 or IL-13 by enzyme-linked immunosorbent assay (ELISA) using antibody pairs purchased from R&D Systems. In some cases, blocking anti-CD1d (clone 42.1) mAb was added at a concentration of 10 µg/ml to test for CD1d dependency.
Cytotoxicity assays
The capacity of α-GalCer and α-S-GalCer to prime CD1d + C1R cells for cytotoxicity by presence of anti-CD107a mAb and monensin (25 µM; Sigma-Aldrich) was added after 1 hour to prevent re-internalisation of CD107a.
DC functional assays
Monocytes were enriched from PBMC isolated from buffy coat packs by positive selection using CD14 Microbeads (Miltenyi Biotec). CD14 + PBMC (containing >90% CD14 + cells)
were allowed to differentiate into immature DC by culturing them at a density of 10 6 cells/ml using 3 ml/well of a 6-well plate (Corning, Amsterdam, Netherlands) in complete RPMI medium made with low-endotoxin FCS (Defined serum, HyClone) containing 50 ng/ml GM-CSF and 70 ng/ml IL-4. Cells were cultured for 6 days, replacing with fresh medium containing cytokines on day 3. Cells in some wells were cultured similarly but in the absence of cytokines, as monocyte controls. On day 6, DC were removed from the wells by aspiration using a wide-gauge Pasteur pipette whereas monocytes were gently scraped from the wells using a cell scraper (Sarstedt, Drinagh, Ireland). Cells were washed with warm RPMI medium. Flow cytometry was used to verify that differentiation into DC had taken place and cells expressed HLA-DR and CD11c but not CD14.
DC were cultured at 0.2x10 6 cells/well in 96-well plates and induced to mature by culturing them for 24 hours in medium alone or with lipopolysaccharide (LPS; 1 µg/ml; Alexis Biochemicals, Exeter, UK), polyinosinic:polycytidylic acid (poly I:C) double stranded RNA (75 µg/ml; Sigma-Aldrich), or equal numbers of allogeneic iNKT cells in the absence or presence of α-GalCer or α-S-GalCer. In some wells PBMC expanded using Methods 1 or 2, as described above for expanding iNKT cells, were included as a noniNKT cell control. After 24 hours, the cell supernatants were assayed for IL-10 and IL12p70 production by ELISA (R&D Systems) and DC were examined for expression of CCR7, CD11c, CD40, CD54, CD80, CD83, CD86 and HLA-DR using flow cytometry.
In vivo studies in mice
Female C57BL/6J mice (Harlan, UK) were injected intravenously with 1 or 2 µg α-GalCer or α-S-GalCer prepared in PBS. PBS-alone was also injected as a vehicle control. Blood
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Statistical analyses
Statistical analysis was carried out using Prism GraphPad Version 5.0. Differences between groups were assessed using the Mann-Whitney U test or paired t test where appropriate. p values of <0.05 were considered significant.
Results
Generation of iNKT cell lines.
iNKT cell lines were generated using Method 1 (PHA, irradiated feeders and IL-2) or Method 2 (anti-CD3 mAb and IL-2) and phenotypically examined by flow cytometry. iNKT cell lines prepared using both methods yielded similar numbers of cells and consisted of CD4 + , CD8 + and CD4 -CD8 -double negative iNKT cells (Figure 2 ), indicating that all three subsets could be expanded.
Human iNKT cells release Th1 and Th2 cytokines in response to α-S-GalCer
presented by CD1d.
iNKT cells expanded using Method 1 (PHA, irradiated feeder cells and IL-2) were cocultured with equal numbers of mock-transfected or CD1d transfected HeLa cells that were unloaded or loaded with varying concentrations of α-GalCer or α-S-GalCer. After 24 hours, supernatants were harvested and assayed for levels of cytokines secreted by ELISA.
Results from 5 experiments using three different iNKT cell lines showed that iNKT cells 
α-S-GalCer-stimulated iNKT cells induce IL-12, and to a lesser degree, IL-10 release by monocyte-derived DC
We also measured the amounts of IL-12 and IL-10 released into supernatants by DC 
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Intravenous administration of α-GalCer, but not α-S-GalCer, to mice resulted in elevated serum IFN-γ and IL-4
Mice were injected intravenously with PBS-alone or PBS containing 1 µg or 2 µg α-GalCer or α-S-GalCer and levels of IFN-γ and IL-4 in serum were measured after 3 and 18 hours
by ELISA. Figure 8 shows that α-GalCer, at either dose, induced the secretion of significant amounts of both cytokines into serum by 3 hours that was sustained to 18 hours.
However, after injection with α-S-GalCer, neither cytokine was detected at elevated levels compared to mice given PBS alone. These data suggest that, unlike α-GalCer, the thioglycoside analogue does not activate murine iNKT cells in vivo.
Discussion
iNKT cells play central roles in innate and adaptive immunity, being capable of killing cells [6] , inducing maturation of DC into antigen-presenting cells [9] [10] [11] [12] , promoting differentiation of B cells into antibody-secreting plasma cells [13, 14] and releasing large quantities of Th1, Th2, Th17 and regulatory T cell cytokines [7, 8, 37, 38] . This early immune stimulatory/regulatory role highlights the potential importance of iNKT cells in infectious, immune-mediated and metastatic disease and therapeutic activation of iNKT cells can prevent and/or reverse a variety of diseases in murine models [15] [16] [17] [18] . Although deficiencies of iNKT cells are found in humans with various diseases [19, 20] , clinical trials for cancer involving α-GalCer stimulation of iNKT cells have not yet demonstrated strong clinical efficacy [21, 22] . One reason for this lack of clinical efficacy may be that iNKT cells are found at ~100-fold lower frequencies in humans compared to mice at most body locations tested [19, 39] . Another may be that like in mice there are different NKT cell subsets with different activities [17, 23, 24] and it is possible that the "wrong" subsets were being used. A third possibility is that murine and human iNKT cell subsets may respond differently to α-GalCer and given the pleiotropy of iNKT cell functions, it is likely that alternative glycolipid ligands may alter iNKT cell responses and may therefore have superior therapeutic value. In this regard, OCH, a synthetic analogue of α-GalCer with a truncated acyl chain and a truncated sphingoid base induces a predominant Th2 response in iNKT cells and confers superior protection against experimental autoimmune encephalomyelitis [28] , collagen-induced arthritis [40] , diabetes [41) and colitis [42) in murine models. Another α-GalCer analogue, α-GalCer C20:2, with a truncated, unsaturated acyl chain was found to have an even stronger protective effect against murine diabetes than OCH [43] . In contrast, synthetic α-GalCer analogues containing aromatic rings in their acyl or sphingosine tails, induced polarized Th1 responses in iNKT cells and thereby conferred superior protection against breast and lung cancers [33, 44] . A C-glycoside analogue of α-GalCer (α-C-GalCer) also induced enhanced Th1 responses through iNKT cells and displayed 1000-fold more potent antimalarial activity and 100-fold greater antimetastatic activity [34] .
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In this report, we show that a thioglycoside analogue of α-GalCer has stimulatory activity for human iNKT cells. Thioglycosides, in which the glycosidic oxygen atom is replaced with a sulphur atom, are tolerated by most biological systems and are more resistant to enzymatic cleavage and chemical degradation [45, 46] . While α-S-GalCer displayed stimulatory activity for human iNKT cells in vitro, we were surprised to find that this glycolipid did not activate murine iNKT cells in vivo, as evidenced by the absence of elevated levels of serum IFN-γ and IL-4. However, in the same mouse experiments and as previously reported [31, 34] , the prototype glycolipid α-GalCer induced rapid secretion of both cytokines into serum. Blauvelt and co-workers [48] also reported no bioactivity of α-S-GalCer in mice. Our finding indicates that murine iNKT cells respond to α-S-GalCer in vivo differentially from human iNKT cells in vitro.
Whether α-S-GalCer stimulates murine iNKT cells in vitro and human iNKT cells in vivo remains to be tested. This difference between antigen recognition by murine and human iNKT cells highlights the importance of testing such therapeutic ligands with human cells.
Our results clearly show that α-S-GalCer exhibits bioactivity by stimulating CD1d-dependent cytotoxic, cytokine and adjuvant activities of iNKT cells similar to those activated by α-GalCer. Two other groups have synthesised similar α-S-GalCer-type analogues but were unable to demonstrate recognition of this compound by iNKT cells.
Chang and co-workers [33] synthesised and tested a number of α-GalCer analogues and found that an α-S-GalCer form presented by monocytes which were co-cultured with human iNKT cells failed to stimulate IFN-γ, IL-2, IL-6, IL-10 or IL-12 release. This compound did induce weak IL-4 production but significantly lower amounts than those induced by α-GalCer. Furthermore, α-S-GalCer did not induce human iNKT cell proliferation, nor did it prolong survival of mice bearing lung or breast tumors, as occurred when α-GalCer was used. In another study, Blauvelt and co-workers [48] administered an α-S-GalCer to non-obese diabetic and C56B1/6 mice but, in accordance with our study, failed to demonstrate expansion of or intracellular cytokine expression by iNKT cells, or proliferation or cytokine production by splenocytes from these mice after restimulation with α-S-GalCer. We are unable to say why our α-S-GalCer showed bioactivity for human iNKT cells while bioactivity was not found in a previous study [33] , but it may reflect the novel procedure used in our study for α-S-GalCer synthesis. In our procedure, an α-galactosyl thiol was prepared from a benzylated 1,6-anhydrogalactose and coupled it with an electrophilic sphingoid iodide under phase transfer conditions [36] . This method yielded S-GalCer exclusively as α-anomers, whereas in the study by Blauvelt and coworkers [48] , the construction of thioglycosidic bond was non-stereoselective, and α-S-
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
18
GalCer had to be isolated from the mixture of α-and β-galactosyl thiols after the coupling reaction. It is possible that low-levels of the β-enantiomer inhibited the effects of the α-form.
In conclusion, we have shown that synthetic α-S-GalCer can stimulate the effector, regulatory and adjuvant activities of human iNKT cells. It is not superior to its parent compound α-GalCer in that it induces the release of the same cytokines with similar potency, it is a similar or less potent stimulator of antitumour cytotoxicity by iNKT cells, and it comparably induces maturation and cytokine secretion by dendritic cells in the presence of iNKT cells. Therefore, α-S-GalCer is unlikely to replace α-GalCer as a therapeutic agent. However, α-S-GalCer may be superior to α-GalCer as a parent compound for developing therapeutic analogues with shorter acyl chains, more double bonds and/or added aromatic groups, as have been introduced to α-GalCer and shown to alter iNKT cell stimulatory capacity [28] [29] [30] [31] [32] [33] [34] [35] and therapeutic efficacy in mice [28, 34, [40] [41] [42] [43] [44] . Thioglycosides are easier to prepare than O-linked glycosides, since sulphur is much more nucleophilic than oxygen, allowing easier formation of the C-S bond. This has enabled several strategies for the synthesis of S-linked glycoconjugates to be developed [36, 46, 49] . Thioglycosides also display increased solubility and stability in biological systems [50] [51] [52] [53] . S-linked glycoconjugates display lower susceptibility to chemical and enzymatic hydrolysis with the rate of hydrolysis of the thioglycosidic bond by glycohydrolases being several orders of magnitude lower that that of the corresponding Olinked glycosides [49] . Furthermore, glycoconjugates with at least one glycosidic oxygen atom replaced with a sulphur atom can act as competitive inhibitors of various glycoside hydrolases [54] . Our demonstration of the bioactivity of α-S-GalCer together its ease of synthesis, flexibility for making analogues and stability in biological systems, places thioglycoside analogues of α-GalCer as potentially superior immune stimulants for human use. 
A C C E P T E D
